Literature DB >> 19351514

Sinus node dysfunction in ATX-II-induced in-vitro murine model of long QT3 syndrome and rescue effect of ranolazine.

Jingjing Wu1, Longxian Cheng, Wim J Lammers, Lin Wu, Xin Wang, John C Shryock, Luiz Belardinelli, Ming Lei.   

Abstract

The aim of this study was to characterize the role of the late Na+ current (I(Na,L)) as a mechanism for induction of both tachy and bradyarrhythmias in murine heart and sino-atrial node tissue. The sea anemone toxin ATX-II and ranolazine were used to increase and inhibit, respectively, I(Na,L). In sixteen hearts studied, exposure to 1-10nM ATX-II caused a slowing of intrinsic heart rate and prolongations of the P-R and QT intervals, the duration of the monophasic action potential, and the sinus node recovery time, accompanied by frequent occurrences of early after depolarisations, delayed after depolarisations and rapid, repetitive ventricular tachy and sino-atrial bradyarrhythmias. ATX-II also slowed sinus node pacemaking, and induced bradycardic arrhythmias in isolated sino-atrial preparations (n=5). The ATX-II-induced alteration of electrophysiological properties and occurrence of arrhythmic events were significantly attenuated by 10 microM ranolazine in intact hearts (n=11) and isolated sino-atrial preparations (n=5). In conclusion, the I(Na,L) enhancer ATX-II causes both tachy and bradyarrhythmias in the murine heart, and these arrhythmias are markedly attenuated by the I(Na,L) blocker, ranolazine (10 microM). The results suggest that I(Na,L) blockade may be the mechanism underlying the reductions of both brady and tachyarrhythmias by ranolazine that were observed during the MERLIN-TIMI clinical outcomes trial.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19351514     DOI: 10.1016/j.pbiomolbio.2009.01.003

Source DB:  PubMed          Journal:  Prog Biophys Mol Biol        ISSN: 0079-6107            Impact factor:   3.667


  6 in total

1.  Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.

Authors:  Ehud Chorin; Dan Hu; Charles Antzelevitch; Aviram Hochstadt; Luiz Belardinelli; David Zeltser; Hector Barajas-Martinez; Uri Rozovski; Raphael Rosso; Arnon Adler; Jesaia Benhorin; Sami Viskin
Journal:  Circ Arrhythm Electrophysiol       Date:  2016-10

2.  Arrhythmogenic calmodulin mutations impede activation of small-conductance calcium-activated potassium current.

Authors:  Chih-Chieh Yu; Jum-Suk Ko; Tomohiko Ai; Wen-Chin Tsai; Zhenhui Chen; Michael Rubart; Matteo Vatta; Thomas H Everett; Alfred L George; Peng-Sheng Chen
Journal:  Heart Rhythm       Date:  2016-05-07       Impact factor: 6.343

Review 3.  Pathophysiology of the cardiac late Na current and its potential as a drug target.

Authors:  Jonathan D Moreno; Colleen E Clancy
Journal:  J Mol Cell Cardiol       Date:  2011-12-16       Impact factor: 5.000

Review 4.  Electrophysiologic basis for the antiarrhythmic actions of ranolazine.

Authors:  Charles Antzelevitch; Alexander Burashnikov; Serge Sicouri; Luiz Belardinelli
Journal:  Heart Rhythm       Date:  2011-03-21       Impact factor: 6.343

Review 5.  Murine Electrophysiological Models of Cardiac Arrhythmogenesis.

Authors:  Christopher L-H Huang
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

6.  Altered sinoatrial node function and intra-atrial conduction in murine gain-of-function Scn5a+/ΔKPQ hearts suggest an overlap syndrome.

Authors:  Jingjing Wu; Yanmin Zhang; Xinzhao Zhang; Longxian Cheng; Wim J Lammers; Andrew A Grace; James A Fraser; Henggui Zhang; Christopher L-H Huang; Ming Lei
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-01-27       Impact factor: 4.733

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.